达能，“健康”增长

Core Insights - Danone reported a 4.2% like-for-like sales growth for the first half of 2024, achieving a positive cycle of volume and price increases [2][3] - The Chinese market emerged as a key growth driver, with record sales and profitability, significantly contributing to the company's overall performance [1][6] Financial Performance - Global sales reached €13.76 billion, with a reported change of -0.1% and a like-for-like change of +4.2% [3][7] - Recurring operating income was €1.75 billion, with a recurring operating margin of 12.7% [3] - Recurring net income attributable to the group was €1.16 billion, reflecting a 5.9% increase [3] Market Dynamics - The professional special nutrition segment grew by 12.9% year-on-year, driven by infant formula and medical nutrition products [4][6] - The Chinese, North Asia, and Oceania region (CNAO) saw a remarkable 11.3% increase in sales, reaching €2.02 billion [7][8] Strategic Initiatives - Danone's "health science" strategy is yielding systematic success, with ongoing acquisitions to strengthen its position in the health and nutrition market [4][12] - The company is expanding its investment in health technology and innovation, particularly in high-end infant formula and medical nutrition products in China [6][12] Product Performance - The "3D乳黄金球" patented formula and medical nutrition products are key contributors to the growth in the Chinese market [1][9] - The Pulse brand successfully launched a collaboration with the mobile game "Genshin Impact," leading to a 7.7% increase in sales for the drinking water segment [11] Future Outlook - Danone reaffirmed its expectation for a 3%-5% like-for-like sales growth for the full year 2025, with operating profit growth expected to outpace sales growth [6] - The company is committed to further investments in health technology and digital empowerment, aiming to establish a global export base for high-end medical nutrition products in China [6][12]